Pfizer halts BCMA trial amid safety woes, hit by DMD delay

Pfizer has paused enrollment in a pivotal trial of its anti-BCMA bispecific antibody after seeing three cases of peripheral neuropathy in an earlier-stage study. The Big Pharma shared the news alongside details of a delay to the start of the U.S. part of its Duchenne muscular dystrophy (DMD) phase 3.